GlassScriptPhysician profile
Laura Cambron
NPI 1922038835
$9,853.08
in general payments reported to CMS, 2019-2025
47 companies · $39.87 in 2025
The $39.87 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,505 · 2022: $3,037 · 2023: $3,418 · 2024: $854 · 2025: $39.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,309 · Education: $2.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,309.18 |
| Education | $2.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $978.48 | 2021-2024 | |
| Livanova USA, INC. | $760.38 | 2021 | |
| Acorda Therapeutics, INC | $619.86 | 2021-2024 | Inbrija |
| Lilly USA, LLC | $508.63 | 2021-2024 | Amyvid, Emgality |
| Argenx US, INC. | $495.95 | 2022-2023 | Vyvgart, Vyvgart Hytrulo |
| Csl Behring | $474.17 | 2021-2023 | Hizentra |
| Alexion Pharmaceuticals, INC. | $442.18 | 2021-2024 | Ultomiris, Soliris |
| Ucb, INC. | $427.44 | 2021-2024 | Rystiggo, Briviact |
| Horizon Therapeutics Plc | $383.18 | 2021-2023 | Uplizna |
| Amgen INC. | $364.67 | 2021-2024 | Uplizna |
| Pfizer INC. | $358.95 | 2022-2024 | |
| Sk Life Science, INC. | $352.15 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $321.04 | 2022-2024 | Ingrezza, Ongentys |
| Biohaven Pharmaceuticals, INC. | $273.87 | 2021 | |
| Neurelis, INC. | $253.37 | 2022-2024 | Valtoco |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Cambron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.